trial

Transcranial Magnetic Stimulation (TMS) for Negative Symptoms in Schizophrenia Spectrum Disorders

NCTId NCT07290738
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 20 (estimated)
Sponsored by The University of Texas Health Science Center, Houston
Primary completion 2030-11-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2026-03-13
Primary completion
2030-11-30
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
TMS

Sponsors

The University of Texas Health Science Center, HoustonLead Sponsor

Investigators

1
Xiaoming Du, PhDPrincipal Investigator

Sites

1 total
Houston, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
NA
Primary Completion Date
2030-11-30
Status
RECRUITING
relationships
The graph out of here
drug
TMS
drug
lead_sponsor
The University of Texas Health Science Center, Houston
company
indication
Schizophrenia Spectrum Disorder
indication
investigator
Xiaoming Du, PhD
person